Sarah Cannon Blood Cancer Network Prominent at Blood and Marrow Transplant Meetings
Presence Reinforces Leadership Position in Transplantation
NASHVILLE, Tenn.--(BUSINESS WIRE)--The Sarah Cannon Blood Cancer Network announced today that 12 abstracts have been accepted for presentation at the 2014 BMT Tandem Meetings. The meetings, which are hosted by The American Society for Blood and Marrow Transplantation (ASBMT) and Center for International Blood & Marrow Transplant Research (CIBMTR), are being held in Grapevine, TX, from February 26 – March 2. During this conference, Sarah Cannon researchers will present findings on the efficacy and treatment standards of blood and marrow transplantation (BMT) for various types of leukemia, lymphoma, and other blood disorders.
“ASBMT celebrates its 20th anniversary this year and I could not be more proud of the accomplishments that we have achieved in advancing transplantation therapies for a diverse group of patient populations.”
“In addition to excellence in research, Sarah Cannon is focusing on transforming cancer care, with a special emphasis on blood cancers,” said Sarah Cannon President, Clinical Operations, Howard A. Burris III, MD. “Through the work of our expert clinicians within the Sarah Cannon Blood Cancer Network, we are elevating standards and improving outcomes.”
Sarah Cannon will also be honoring C. Fred LeMaistre, MD, vice president and physician-in-chief of Hematology, who is completing his term as president of ASBMT at the 2014 Tandem Meetings. During his tenure, LeMaistre led strategic planning for BMT program growth including technology integration to improve standards and processes for clinicians, as well as a program for mentoring physicians at earlier stages of their careers. Under his leadership, special interest groups of allied healthcare professionals were integrated into the society. Together with the National Marrow Donor Program, the ASBMT multi-disciplinary teams tackled capacity issues for transplant centers. LeMaistre will be leading several portions of the meeting along with chairing a joint session with the president of the European Bone Marrow Transplant Group for abstracts being presented with scientific advances in allogeneic transplants.
“Our work in BMT is a team effort and I have been honored to collaborate with my ASBMT and CIBMTR colleagues to set a new course for the expansion and improvement of BMT standards,” said LeMaistre. “ASBMT celebrates its 20th anniversary this year and I could not be more proud of the accomplishments that we have achieved in advancing transplantation therapies for a diverse group of patient populations.”
The 2014 BMT Tandem meetings bring together more than 3,000 physicians, investigators and other healthcare professionals promoting blood and marrow transplantation and cellular therapy research, education, scholarly publication and clinical standards. A full list of Sarah Cannon’s abstracts can be accessed at sarahcannon.com.
About The Sarah Cannon Blood Cancer Network
The Sarah Cannon Blood Cancer Network is one of the largest providers of blood cancer care including blood and marrow transplantation (BMT) across the United States and United Kingdom. Its network conducts over 850 transplants annually and has treated more than 9,500 patients since the inception of our first program. Through its commitment to the highest level of quality standards, infrastructure, training and research, the Sarah Cannon Blood Cancer Network provides an unparalleled experience for patients seeking treatment. For more information about the Blood Cancer Network and Sarah Cannon’s full suite of oncology services, please visit: sarahcannon.com.